Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stroke drug aims to boost brain recovery after clot removal

NCT ID NCT05559398

Completed Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This clinical trial tests whether adding the drug glenzocimab to standard endovascular therapy (a procedure to remove blood clots) improves recovery in people with acute ischemic stroke. The study includes adults aged 18 and older who are eligible for clot removal within 24 hours of stroke onset. The main goal is to see if glenzocimab reduces disability at 90 days compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
glenzocimab
What this could lead to
If successful, glenzocimab could become a standard add-on treatment to improve recovery and reduce disability after a stroke.
What could go wrong
This is a mid-stage trial with only 108 participants, so results may not be conclusive. The drug may not improve outcomes or could cause bleeding risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STROKE ISCHEMIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STROKE ISCHEMIC STROKE, ACUTE

Contacts and locations

Locations

  • CHRU Nancy Hopital central

    Nancy, France

  • CHRU Tours - Hôpital Bretonneau

    Tours, France

  • CHU Dupuytren

    Limoges, France

  • CHU Timone

    Marseille, France

  • Hospices Civils de Lyon

    Bron, France

  • Hôpital Foch

    Suresnes, France

  • Hôpital Gui de Chauliac

    Montpellier, France

  • Hôpital Lariboisière AP-HP

    Paris, France

  • Hôpital Pierre Paul Riquet

    Toulouse, France

  • Hôpital Sainte Anne

    Paris, France

  • Hôpital de Hautepierre

    Strasbourg, France

  • Hôpital fondation Adolphe de Rothschild

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.